Research Article

Clinical Outcomes of Ileostomy Closure before Adjuvant Chemotherapy after Rectal Cancer Surgery: An Observational Study from a Chinese Center

Zhen Sun,1,2 Yufeng Zhao,1,2 Lu Liu,1,2 and Jichao Qin1,2

1Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei, China
2Tongji Cancer Research Institute, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei, China

Correspondence should be addressed to Zhen Sun; sunzhen5231@qq.com, Lu Liu; halesan@163.com, and Jichao Qin; jcqin@tjh.tjmu.edu.cn

Received 20 February 2021; Accepted 24 June 2021; Published 14 July 2021

Academic Editor: Zhongguang Luo

Copyright © 2021 Zhen Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The optimal timing of temporary ileostomy closure with respect to the time of adjuvant chemotherapy following sphincter-saving surgery for rectal cancer remains unclear. The aim of this study is to investigate the clinical and oncological outcomes of ileostomy closure before, during, and after adjuvant chemotherapy following curative rectal cancer resection.

Methods. Patients diagnosed with rectal adenocarcinoma who underwent low anterior resection and temporary loop ileostomy during May 2015 and September 2019 were retrospectively evaluated. Patients undergoing ileostomy closure before adjuvant chemotherapy (Group I) were compared to patients undergoing closure during (Group II) and after (Group III) adjuvant chemotherapy.

Results. A total of 225 patients were evaluated for eligibility, and 132 were finally selected and divided into 3 groups (24 in Group I, 53 in Group II, and 55 in Group III). No significant differences were observed in operative time, postoperative hospital stay, postoperative complications, total adjuvant chemotherapy cycles, and low anterior resection syndrome scores among the three groups. There was no significant difference in disease-free survival ($p=0.834$) and overall survival ($p=0.462$) between the three groups. Conclusion. Temporary ileostomy closure before adjuvant chemotherapy following curative rectal cancer resection can achieve a clinical and oncological safety level equal to stoma closure during or after chemotherapy in selected patients.

1. Introduction

A temporary diverting ileostomy is frequently performed on patients who have had rectal cancer surgery to protect anastomosis, particularly for rectal cancer of the middle and lower third [1, 2]. Previous studies have demonstrated that patients with a temporary diverting ileostomy were at lower risk to suffer from anastomotic leakage, peritonitis, and their associated morbidity and mortality than those without it [3, 4].

There are some agreements among surgeons that ileostomy closure should not be performed earlier than 60–90 days [5, 6]. However, a diverting stoma has various adverse effects including stoma-related morbidities, physical stress, and psychological handicap, which affect the patients’ quality of life [7, 8]. Therefore, patients suffering from considerable pressure are eager to close the diverting stoma after primary surgery; however, there are no strict recommendations for the optimal timing of ileostomy closure. Recently, several studies have addressed the safety and feasibility of early ileostomy closure (within 2 weeks after primary surgery) and reported promising results [9–11]. After rectal cancer surgery, the outcomes of early versus late closure of loop ileostomy have been studied; however, the outcomes remain controversial with respect to adjuvant chemotherapy. Studies showed that temporary ileostomy closure before [12, 13] or during [14–17]
adjoint chemotherapy following rectal cancer surgery had similar outcomes to the closure of ileostomy after adjuvant chemotherapy. On the contrary, other studies showed that a shorter interval between primary surgery and ileostomy closure may negatively affect the completeness of chemotherapy resulting from stoma-related complications such as anastomotic leakage or incomplete anorectal function [18–20]. In addition, stoma closure before or during adjuvant chemotherapy may induce the delay or interruption of chemotherapy, which may alter the effects of chemotherapy [21, 22].

Considering the controversies regarding the optimal timing of temporary ileostomy closure with respect to the time of delivering adjuvant chemotherapy, our goal was to investigate the outcomes of ileostomy closure before, during, and after adjuvant chemotherapy following curative rectal cancer surgery.

2. Method

2.1. Patients and Interventions. Patient data was extracted from a prospectively collected colorectal cancer database retrospectively. Patients diagnosed with rectal adenocarcinoma who received low anterior resection with total mesorectal excision (TME) and temporary loop ileostomy closure between May 2015 and September 2019 were included. Informed consent had been obtained from individual patients, and the present study had been approved by the institutional review board of the hospital.

Exclusion criteria included patients with stage IV rectal cancer and postoperative radiotherapy or patients who suffered complications of anastomosis from the index surgery. Patients who did not undergo adjuvant chemotherapy were also excluded.

We divided our patients into three groups: Group I, Group II, and Group III, who underwent ileostomy closure before, during, and after chemotherapy, respectively. The demographics and clinical characteristics were compared between the groups.

The anastomosis site was assessed with contrast enema, abdominopelvic computed tomography, or/and colorectal endoscopy to ensure the safety of the ileostomy closure. The ileostomy closure technique included handsewn or stapled ileo-ileal anastomosis, which was left to the discretion of the surgeon. Eight different gastrointestinal surgeons working in the same institution performed all procedures.

2.2. Outcomes. The compared parameters included details of surgical procedures, demographics, clinical characteristics, stoma closure, length of hospital stay, information of adjuvant chemotherapy, complications related to the stoma formation, prevalence of low anterior resection syndrome (LARS), disease recurrence, and survival.

The stoma formation-related complications were extracted retrospectively by inspection of patient charts filled in by stoma care therapists. High volume output was defined as the combination of stoma content output of more than 1000 ml and electrolyte disturbance. Skin irritation included parastomal infection, rash, pain, or ecchymoma. Stoma closure-related complications were assessed within 30 days after ileostomy closure.

The overall survival (OS) was presented by the interval between index surgery and death, while the disease-free survival (DFS) was defined by the interval between index surgery and the date of the first recurrence (local and/or distant). Data on patients who were disease-free were censored from the date of the last follow-up until May 2020. Meanwhile, a LARS score questionnaire [23] was completed by the follow-up telephone calls to the surviving participants. The associated response categories were based on the frequency of symptom occurrence or number of bowel motions. A LARS score of 0–20 was interpreted as no LARS; 21–29, minor LARS; and 30–42, major LARS [23].

2.3. Statistical Analysis. Continuous parameters were presented as the mean and standard deviation and were further analyzed using one-way analysis of variance. The categorical parameters were described using percentages, the chi-squared test, or the Fisher exact test. The survival curve between groups regarding OS and DFS was calculated by Kaplan-Meier analysis and compared with the log-rank test. SPSS statistical software version 19.0 (SPSS Inc., Chicago, IL, USA) for Windows and GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA) were applied for all data analyses. \( p < 0.05 \) was considered statistically significant.

3. Results

A total of 225 patients were evaluated for eligibility, and 132 were included and divided into three groups in the present study; Group I consisted of 24 patients and underwent ileostomy closure before chemotherapy; Group II consisted of 53 patients and underwent it during chemotherapy; and Group III consisted of 55 patients and underwent it after chemotherapy (Figure 1). The demographics and clinicopathologic characteristics among the three groups were comparable (Table 1). The preoperative BMI (body mass index) of patients in Group III was higher, and the difference nevertheless was not statistically significant.

The mean duration of the diverting stoma was 25.9 ± 5.3 days in Group I, 119.3 ± 47.5 days in Group II, and 202.3 ± 93.8 days in Group III (\( p < 0.0001 \)) (Table 2). Intraoperative features such as the operative time and anastomosis method were comparable among the three groups. Notes about unexpected difficulties including mobilization of ileum adhesion or mobilization of ileostomy from the abdominal were described more often in Group I than the other two groups (29.2% in Group I vs. 11.3% in Group II and 9.1% in Group III, \( p = 0.047 \)). No significant difference was observed in the interval for resuming diet, passing of gas, postoperative 30-day mortality, reoperation rate, and total adjuvant chemotherapy. The postoperative hospital stay was longer, but not statistically significant, in Group I than the others (8.6 ± 2.2 days in Group I vs. 7.5 ± 2.5 days in Group II and 7.5 ± 2.1 days in Group III, \( p = 0.121 \)). The mean interval between index surgery and first adjuvant chemotherapy was 51.5 ± 7.0 days in Group I, 33.8 ± 12.4 days in Group II, and 30.2 ± 9.7 days in Group III (\( p < 0.0001 \)).
Overall, no significant difference was detected among the three groups regarding the incidence of stoma formation-related complications. Six (10.9%) patients in Group III had skin irritation after stoma formation, significantly higher than Group I (4.2%) and Group II (0.0%) \((p = 0.039)\) (Table 3). One patient from Group I underwent stoma closure during the index surgery admission period for stoma prolapse and skin irritation. None of the patients required emergency surgery due to high volume output or postoperative ileus. Overall, the incidence of stoma closure-related complications was 20.8% in Group I, 13.2% in Group II, and 12.7% in Group III, which was not statistically different. No fistula and anastomotic leakage were observed among all three of the groups. The wound infection rate was higher but not significant in Group I (12.5%) than in Group II (7.5%) and Group III (9.1%) \((p = 0.783)\). Two patients in Group III and one patient in Group II underwent reoperation due to incisional hernia on the stoma closure site 1 month after ileostomy closure. In addition, one patient in Group I underwent reoperation for postoperative ileus who did not succeed in conservative treatment.

126 of the original 132 participants were available in the survival analysis. The average follow-up period in Group I was \(731 \pm 332\) days; in Group II, \(977 \pm 399\) days; and in Group III, \(897 \pm 389\) days. No differences were found in OS and DFS among the three groups \((p = 0.462\) for OS and \(p = 0.834\) for DFS) (Figure 2).

The LARS score questionnaire was completed by all 106 surviving patients among the 126 participants for survival analysis. The demographics and clinicopathologic characteristics between the three groups among these participants were comparable. Overall, the incidence of LARS was 50.0% in Group I, 54.7% in Group II, and 47.7% in Group III. The median LARS scores for Groups I-III were 17 (interquartile range 6-29), 24 (14-32), and 20 (8-31), respectively \((p = 0.282)\). No significant differences were noticed regarding incontinence to feces and flatus, increased stool frequency, clustering, and urgency among the three groups (Table 4).

### 4. Discussion

In this study, we compared the postoperative morbidity and mortality of ileostomy closure before, during, and after adjuvant chemotherapy after the curative rectal cancer resection and tried to find out whether survival rates and recurrence are associated with the time until closure. We found that in selected patients, temporary ileostomy closure before adjuvant chemotherapy could achieve a clinical safety level equal to stoma closure during or after chemotherapy in terms of postoperative complication, LARS, and oncological prognosis.

There is uncertainty about the timing of the closure of ileostomy since most patients with rectal cancer are likely to receive postoperative adjuvant chemotherapy. The interval between creation and closure of the temporary stoma is often delayed in rectal cancer patients who had received adjuvant chemotherapy \([24–26]\). These patients suffered more stoma-related complications before closure which negatively
impact their quality of life [7, 8, 27]. Whether the closure of a
temporary stoma can be done before or during adjuvant che-
motherapy instead of after needs clear guidelines. Thalhei-
mer et al. [12] found that fewer complications happened in
the cases of ileostomy closure performed before (12.5%) the
start of adjuvant chemotherapy or radiochemotherapy,
rather than during (42.9%) or after (21.2%). They speculated
that the higher complication rates in the latter two groups
might be because of the patients’
compromised general phys-
ical condition during and after the adjuvant therapy lasting
up to 6 months, such as decreased wound healing capacity.
Furthermore, Lordan et al. [24] pointed out that it would
be feasible to close the temporary stoma before starting adju-
vant therapy because most times the postoperative therapy is
not initiated in 2-3 weeks after the anterior resection. This
would decrease the incidence of stoma-related complications
and avoid a long delay in closure after adjuvant therapy.
Recently, Klęk et al. [13] reported that ileostomy closure per-
formed in advance of adjuvant chemotherapy was safe and
should be considered part of the enhanced recovery after sur-
gery (ERAS) protocol. In our study, we found that stoma
formation-related complication rates in Group III were
higher than those in Group I or Group II. In particular, the
patients in Group III su
ff
ed more skin irritation than those
in the other two groups. Therefore, patients su
ff
ering from
considerable pressure tend to choose to close the diverting
stoma at an early stage.

In the present study, pairwise comparisons among all
groups indicated that there were no significant differences
between them in the stoma closure-related complications,
reoperation rate, and mortality. Some notes about unex-
pected difficulties were described more often in Group I than

| Table 1: Demographics and clinicopathologic characteristics of the study groups. |
|---------------------------------|---------------------------------|---------------------------------|---------------------|
|                                 | Group I (n = 24)                | Group II (n = 53)               | Group III (n = 55)   |
| Sex                             | 16 (66.7%)                      | 41 (77.4%)                      | 32 (58.2%)           | 0.104               |
| Male                            | 8 (33.3%)                       | 12 (22.6%)                      | 23 (41.18%)          |                     |
| Female                          | 57.2 ± 9.7                      | 56.3 ± 10.0                     | 53.7 ± 11.2          | 0.304               |
| Age (years)                     | 21.1 ± 2.4                      | 22.3 ± 3.4                      | 22.8 ± 2.7           | 0.073               |
| BMI* (kg/m²)                    | 2 (8.3%)                        | 8 (15.1%)                       | 12 (21.8%)           | 0.310               |
| Comorbidity                     |                                 |                                 |                     |                     |
| Cardiovascular diseases         | 2 (8.3%)                        | 8 (15.1%)                       | 12 (21.8%)           |                     |
| Diabetes                        | 0 (0.0%)                        | 6 (4.5%)                        | 3 (2.3%)             | 0.165               |
| Pulmonary diseases              | 1 (4.2%)                        | 1 (1.9%)                        | 1 (1.8%)             | 0.789               |
| Renal diseases                  | 0 (0.0%)                        | 1 (1.9%)                        | 2 (3.6%)             | 0.590               |
| ASA class                       |                                 |                                 |                     | 0.961               |
| I                               | 3 (12.5%)                       | 5 (9.4%)                        | 4 (7.3%)             |                     |
| II                              | 19 (79.2%)                      | 44 (83.0%)                      | 47 (85.5%)           |                     |
| III                             | 2 (8.3%)                        | 4 (7.5%)                        | 4 (7.3%)             |                     |
| Type of surgery                 |                                 |                                 |                     | 0.994               |
| Laparoscopic                     | 23 (95.8%)                      | 51 (96.2%)                      | 53 (96.4%)           |                     |
| Conversion to open              | 1 (4.2%)                        | 2 (3.8%)                        | 2 (3.6%)             |                     |
| cTNM stage                      |                                 |                                 |                     | 0.706               |
| I                               | 1 (4.2%)                        | 5 (9.4%)                        | 4 (7.3%)             |                     |
| II                              | 5 (20.8%)                       | 17 (32.1%)                      | 33 (21.8%)           |                     |
| III                             | 18 (75.0%)                      | 33 (62.3%)                      | 39 (70.9%)           |                     |
| ypTNM stage**                   |                                 |                                 |                     | 0.471               |
| 0                               | 1 (4.2%)                        | 0 (0.0%)                        | 1 (1.8%)             |                     |
| I                               | 2 (8.3%)                        | 4 (7.5%)                        | 9 (16.4%)            |                     |
| II                              | 12 (50.0%)                      | 25 (47.2%)                      | 28 (50.9%)           |                     |
| III                             | 9 (37.5%)                       | 24 (45.3%)                      | 17 (30.9%)           |                     |
| Neoadjuvant CRT                 | 10 (41.7%)                      | 19 (38.5%)                      | 25 (45.5%)           | 0.595               |
| Tumor location*** (cm)          | 8.2 ± 3.8                       | 7.5 ± 3.6                       | 8.0 ± 3.7            | 0.698               |
| 3-5                             | 9 (37.5%)                       | 22 (41.5%)                      | 16 (29.1%)           | 0.597               |
| 6-10                            | 9 (37.5%)                       | 23 (43.4%)                      | 27 (49.1%)           |                     |
| 11-15                           | 6 (25.0%)                       | 8 (15.1%)                       | 12 (21.8%)           |                     |

Values are presented as the mean ± standard deviation or number of patients (%). * Measured before ileostomy closure. ** Pathological stage according to UICC. *** Tumor lower border from the anal verge. BMI: body mass index; ASA: American Society of Anesthesiologists; UICC: Union Internationale Contre le Cancer; CRT: chemoradiotherapy.
Table 2: Details of loop ileostomy closure.

|                         | Group I (n = 24) | Group II (n = 53) | Group III (n = 55) | p value |
|-------------------------|------------------|-------------------|-------------------|---------|
| Interval to ileostomy closure (day) | 25.9 ± 5.3 | 119.3 ± 47.5 | 202.3 ± 93.8 | <0.001  |
| Operative time (min)   | 139.8 ± 30.8 | 132.2 ± 26.9 | 130.3 ± 25.0 | 0.344   |
| Anastomosis (ileo-ileoanastomosis) |        |                   |                  | 0.613   |
| Handsewn              | 14 (58.3%) | 37 (69.8%) | 36 (65.5%) |         |
| Stapled               | 10 (41.7%) | 16 (30.2%) | 19 (34.5%) |          |
| Noted unexpected difficulties during surgery | 7 (29.2%) | 6 (11.3%) | 5 (9.1%) | 0.047   |
| Time until passing of gas (day) | 3.1 ± 0.7 | 3.0 ± 0.6 | 2.8 ± 0.6 | 0.069   |
| Time until fully oral nutrition (day) | 2.8 ± 1.1 | 2.6 ± 0.7 | 2.4 ± 0.7 | 0.108   |
| Stoma formation-related complications | 3 (13.0%) | 9 (17.0%) | 11 (20.0%) | 0.755   |
| Stoma closure-related complication | 5 (20.8%) | 7 (13.2%) | 7 (12.7%) | 0.697   |
| Postoperative 30-day mortality | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Reoperation            | 1 (4.2%) | 1 (1.9%) | 2 (3.6%) | 0.815   |
| Hospital stay after closure (day) | 8.6 ± 2.2 | 7.5 ± 2.5 | 7.5 ± 2.1 | 0.121   |
| Total adjuvant chemotherapy (cycle) | 5.2 ± 2.0 | 5.7 ± 1.4 | 4.9 ± 2.0 | 0.060   |
| Interval between index surgery and 1st chemotherapy (day) | 51.5 ± 7.0 | 33.8 ± 12.4 | 30.2 ± 9.7 | <0.001 |

Values are presented as the mean ± standard deviation or number of patients (%). NA: not available.

Table 3: Stoma-related complications.

|                         | Group I (n = 24) | Group II (n = 53) | Group III (n = 55) | p value |
|-------------------------|------------------|-------------------|-------------------|---------|
| Stoma formation-related complications | 3 (13.0%) | 9 (17.0%) | 11 (20.0%) | 0.755   |
| High volume output      | 1 (4.2%) | 5 (9.4%) | 5 (9.1%) | 0.715   |
| Adhesive ileus          | 1 (4.2%) | 4 (7.5%) | 3 (5.5%) | 0.822   |
| Parastomal hernia       | 1 (4.2%) | 0 (0%) | 2 (3.6%) | 0.353   |
| Prolapse                | 1 (4.2%) | 0 (0%) | 0 (0%) | 0.104   |
| Skin irritation          | 1 (4.2%) | 0 (0%) | 6 (10.9%) | 0.039   |
| Stoma closure-related complications | 5 (20.8%) | 7 (13.2%) | 7 (12.7%) | 0.697   |
| Wound infection          | 3 (12.5%) | 4 (7.5%) | 5 (9.1%) | 0.783   |
| Adhesive ileus          | 2 (8.3%) | 2 (3.8%) | 1 (1.8%) | 0.378   |
| Fistula/anastomotic leakage | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Incisional hernia       | 0 (0%) | 1 (1.9%) | 2 (3.6%) | 0.590   |

Values are presented as the number of patients (%). NA: not available.

Figure 2: Kaplan-Meier curves of survival between the three groups: (a) disease-free survival and (b) overall survival.
In the present study, the mean interval between index surgery and first adjuvant chemotherapy was 51.5 ± 7.0 days in Group I, suggesting that patients in the early ileostomy closure group did not significantly exceed recommended duration between radical surgery and the start of chemotherapy. In addition, our results showed that no significant differences were found in OS and DFS among the three groups, thus indicating that early stoma closure before adjuvant chemotherapy did not affect oncological outcomes [15, 17]. However, some surgeons and oncologists are reluctant to stoma closure before adjuvant chemotherapy because it is associated with a 17% postoperative morbidity rate [32], which may affect the initiation of adjuvant chemotherapy. Although the clinical and oncological outcomes are comparable among groups in the present study, the mean duration of the diverting stoma was 25.9 ± 5.3 days in Group I which is still relatively longer than other studies [9–11]. In order to start the adjuvant treatment in time, the ileostomy closure time needs to be shortened. In the future, our center will initiate a randomized controlled study in which the safety and feasibility of ileostomy closure will be evaluated 14 days after index surgery. In addition, a method to reduce postoperative morbidity should also be considered to shorten the interval of the ileostomy closure and the first chemotherapy. Two patients in Group I wanted more recovery time because of the postoperative ileus. The delay of adjuvant chemotherapy in these patients should be taken into account, and excessive delay should be prevented in adjuvant treatment. Among the 3 patients that required treatment for an ileostomy closure wound, the adjuvant chemotherapy was about 1 week delayed. In such cases, chemotherapy might not be delayed if the preoperative nutrition support or purse-string skin closure technique was taken into account. In addition, patients who underwent postoperative radiotherapy were not included in the present study because such treatment strategy may increase the risk of anastomotic leakage [33] and prolong the stoma closure time. In the future, ileostomy closure before chemotherapy should only be proposed for carefully selected patients without any signs of anastomotic leakage and uneventful postoperative outcomes. Therefore, in order to improve this selection process, another study to determine the risk factors for complications after loop ileostomy closure following sphincter-saving surgery with respect to adjuvant chemotherapy is ongoing in our center.

Table 4: Details of LARS at follow-up 12 months after index surgery.

|                          | Group I (n = 20) | Group II (n = 42) | Group III (n = 44) | p value |
|--------------------------|-----------------|------------------|-------------------|---------|
| 12-month median LARS scores (IQR) | 17 (6-29) | 24 (14-32) | 20 (8-31) | 0.282  |
| Major LARS, n (%)     | 5 (25.0%)       | 14 (33.3%)      | 14 (31.8%)       | 0.796   |
| Minor LARS, n (%)     | 5 (25.0%)       | 9 (21.4%)       | 7 (15.9%)        | 0.660   |
| Incontinence to feces, n (%) | 8 (40.0%) | 19 (45.2%) | 15 (31.4%) | 0.572   |
| Flatus, n (%)         | 1 (5.0%)        | 3 (7.1%)        | 5 (11.4%)        | 0.644   |
| Increased stool frequency, n (%) | 10 (50.0%) | 28 (66.7%) | 21 (47.7%) | 0.179   |
| Clustering, n (%)     | 14 (70.0%)      | 36 (85.7%)      | 30 (68.2%)       | 0.138   |
| Urgency, n (%)        | 10 (50.0%)      | 27 (64.3%)      | 26 (59.1%)       | 0.563   |

Values are presented as the number of patients (%). LARS: low anterior resection syndrome; IQR: interquartile range.
LARS is frequently reported in patients with rectal cancer who received TME with low colorectal anastomosis. The disordered defecatory function during LARS, such as increased stool frequency, clustering, urgency, and incontinence to feces and flatus after sphincter-saving procedures, negatively affects the patient’s quality of life [34]. Opinions on the effect of a diverting stoma on the incidence and severity of anorectal functional alterations after anterior resection are controversial. In addition, the relationship between the timing of ileostomy closure and LARS is rarely reported. The pathophysiology leads us to believe that the disuse colitis and delayed restoration of bowel continuity may result in alterations in colonic nutrition, causing inflammation, changes in the bacterial flora and irreversible colon, and rectal atrophy of motility or sensory elements [23, 35, 36]. Recently, a prospective randomized controlled trial found earlier closure of ileostomy after anterior resection had a better LARS score than the later closure group, although the difference was not statistically significant. Several noncontrolled studies have also shown an association between the use of a diverting stoma and LARS in univariate analysis, indicating that the timely restoration of bowel continuity might avoid the irreversible colon and rectal atrophy and reduce the incidence of LARS [37–39]. However, confounding factors such as age, gender, tumor location, and perioperative radiotherapy need to be considered when interpreting these results. Notably, some other studies have found no difference in anorectal function between patients with and without a temporary defunctioning stoma [40, 41]. In the present study, the median LARS score in Group I was better than that in the other two groups, indicating that the early ileostomy closure might improve functional outcomes in these patients. Alternatively, a temporary loop ileostomy closure before adjuvant chemotherapy is comparable with the closure of ileostomy during or after adjuvant chemotherapy regarding the anorectal function. The controversial results mentioned above suggest that it is essential to apply powered prospective randomized studies to evaluate definitively whether early closure of an ileostomy could decrease the development of LARS.

Our study had some limitations, namely, because it is retrospective. Next, a lack of randomization to different groups creates bias. Surgeon preference and patient desire affect this selection. While some surgeons in this study were used to perform ileostomy closure after completion of chemotherapy, other surgeons choose to close an ileostomy during or before chemotherapy. Patient status such as systemic illness, variables during index surgery, or stoma formation-related complications may also play an important role in affecting this selection. In addition, a surgeon’s decision is compromised due to a patient’s strong desire to close the stoma. Nevertheless, our study has its advantages due to the sparse literature available reporting the safety of ileostomy closure before adjuvant chemotherapy regarding postoperative complications, which provides some hints for clinicians to make better clinical decisions on the optimal timing of ileostomy closure with respect to adjuvant chemotherapy. Furthermore, this is the first study comparing the effect of ileostomy closure before and during or after adjuvant chemotherapy on oncologic outcomes.

In conclusion, our findings suggest that after colorectal cancer resection, performing temporary loop ileostomy closure before adjuvant chemotherapy has comparable effects with the closure of ileostomy during or after adjuvant chemotherapy in terms of postoperative complication, LARS, and oncological prognosis in selected patients. A well-planned larger-scale, randomized, controlled trial with a long follow-up should be performed to accurately define which individuals benefit from early closure of ileostomy before adjuvant chemotherapy and to assess this strategy with regard to the quality of life and compliance of adjuvant chemotherapy.

Data Availability

Data are available on request from the authors.

Ethical Approval

This trial was approved by the institutional ethical review board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Authors’ Contributions

ZS and LL developed the conception and designed the study. ZS and YZ collected the data. ZS did the analysis and interpretation of data. ZS, LL, and JQ conceptualized and wrote the manuscript. The grant given to ZS financed this study. All the authors approved the version to be published.

Acknowledgments

We are grateful for surgery support by Dr. Dan Huang, Dr. Xin Wei, Dr. Xuexi Luo, Dr. Yongdong Feng, Dr. You Zou, Dr. Yi Zhou, Dr. Peng Zhang, Dr. Yixin Tong, and Dr. Chun Gao and the personnel of the nursing department. This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81802655).

References

[1] N. Hüser, C. W. Michalski, M. Erkan et al., “Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery,” Annals of Surgery, vol. 248, no. 1, pp. 52–60, 2008.

[2] W. S. Tan, C. L. Tang, L. Shi, and K. W. Eu, “Meta-analysis of defunctioning stomas in low anterior resection for rectal cancer,” The British Journal of Surgery, vol. 96, no. 5, pp. 462–472, 2009.

[3] A. Montedori, R. Cirocchi, E. Farinella, F. Sciannameo, and I. Abrah, “Covering ileo- or colostomy in anterior resection for rectal carcinoma,” Cochrane Database of Systematic Reviews, vol. 5, article CD006878, 2010.

[4] K. Mrak, S. Uranitsch, F. Pedross et al., “Diverting ileostomy versus no diversion after low anterior resection for rectal
cancer: a prospective, randomized, multicenter trial,” *Surgery*, vol. 159, no. 4, pp. 1129–1139, 2016.

[5] M. F. Sier, L. van Gelder, D. T. Ubbink, W. A. Bemelman, and R. J. Oostenbroek, “Factors affecting timing of closure and non-reversal of temporary ileostomies,” *International Journal of Colorectal Disease*, vol. 30, no. 9, pp. 1185–1192, 2015.

[6] K. L. Sherman and S. D. Waxner, “Considerations in stoma reversal,” *Clinics in Colon and Rectal Surgery*, vol. 30, no. 3, pp. 172–177, 2017.

[7] H. B. Neuman, S. Patil, S. Fuzesi et al., “Impact of a temporary stoma on the quality of life of rectal cancer patients undergoing treatment,” *Annals of Surgical Oncology*, vol. 18, no. 5, pp. 1397–1403, 2011.

[8] H. B. Neuman, J. Park, S. Fuzesi, and L. K. Temple, “Rectal cancer patients’ quality of life with a temporary stoma: shifting perspectives,” *Diseases of the Colon and Rectum*, vol. 55, no. 11, pp. 1117–1124, 2012.

[9] K. H. Lee, H. O. Kim, J. S. Kim, and J. Y. Kim, “Prospective study on the safety and feasibility of early ileostomy closure 2 weeks after lower anterior resection for rectal cancer,” *Annals of Surgical Treatment and Research*, vol. 96, no. 1, pp. 41–46, 2019.

[10] A. K. Danielsen, J. Park, J. E. Jansen et al., “Early closure of a temporary ileostomy in patients with rectal cancer: a multicenter randomized controlled trial,” *Annals of Surgery*, vol. 265, no. 2, pp. 284–290, 2017.

[11] B. Menaheh, J. Lubrano, A. Vallois, and A. Alves, “Early closure of defunctioning loop ileostomy: is it beneficial for the patient? A meta-analysis,” *World Journal of Surgery*, vol. 42, no. 10, pp. 3171–3178, 2018.

[12] A. Thalheimer, M. Bueter, M. Kortuem, A. Thiede, and S. K. Adhikari, “Early closure of the protective ileostomy after rectal resection should become part of the enhanced recovery after surgery (ERAS) protocol: a randomized, prospective, two-center clinical trial,” *Wideochir Inne Tech Maloinwazyjne*, vol. 13, no. 4, pp. 435–441, 2018.

[13] S. Klęk, M. Pisarska, K. Milian-Ciesielska et al., “Early closure of the protective ileostomy after rectal resection should become part of the enhanced recovery after surgery (ERAS) protocol: a randomized, prospective, two-center clinical trial,” *Wideochir Inne Tech Maloinwazyjne*, vol. 13, no. 4, pp. 435–441, 2018.

[14] S. Hajibandeh, S. Hajibandeh, D. R. Sarma et al., “Meta-analysis of temporary loop ileostomy closure during or after adjuvant chemotherapy following rectal cancer resection: the dilemma remains,” *International Journal of Colorectal Disease*, vol. 34, no. 7, pp. 1151–1159, 2019.

[15] Y. J. Choi, J. M. Kwak, N. Ha et al., “Clinical outcomes of ileostomy closure according to timing during adjuvant chemotherapy after rectal cancer surgery,” *Ann Coloproctol*, vol. 35, no. 4, pp. 187–193, 2019.

[16] B. H. Kye, H. J. Kim, J. G. Kim, and H. M. Cho, “Is it safe the reversal of a diverting stoma during adjuvant chemotherapy in elderly rectal cancer patients?”, *International Journal of Surgery*, vol. 12, no. 12, pp. 1337–1341, 2014.

[17] H. Tulchinsky, E. Shacham-Shmueli, J. M. Klausner, M. Inbar, and R. Geva, “Should a loop ileostomy closure in rectal cancer patients be done during or after adjuvant chemotherapy?”, *Journal of Surgical Oncology*, vol. 109, no. 3, pp. 266–269, 2014.

[18] F. Sandra-Petrescu, F. Herrle, A. Hinke et al., “CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer,” *BMC Cancer*, vol. 15, no. 1, p. 923, 2015.

[19] A. Bausys, J. Kulivas, A. Dulsakas et al., “Early versus standard closure of temporary ileostomy in patients with rectal cancer: a randomized controlled trial,” *Journal of Surgical Oncology*, vol. 120, no. 2, pp. 294–299, 2019.

[20] L. Zhen, Y. Wang, Z. Zhang et al., “Effectiveness between early and late temporary ileostomy closure in patients with rectal cancer: a prospective study,” *Current Problems in Cancer*, vol. 41, no. 3, pp. 231–240, 2017.

[21] J. J. Biagi, M. J. Raphael, W. J. Mackillop, W. Kong, W. D. King, and C. M. Booth, “Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis,” *JAMA*, vol. 305, no. 22, pp. 2335–2342, 2011.

[22] G. Des Guetz, P. Nicolas, G. Y. Perret, J. F. Morere, and B. Uzzan, “Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis,” *European Journal of Cancer*, vol. 46, no. 6, pp. 1049–1055, 2010.

[23] C. Keane, J. Park, S. Öberg et al., “Functional outcomes from a randomized trial of early closure of temporary ileostomy after rectal excision for cancer,” *The British Journal of Surgery*, vol. 106, no. 5, pp. 645–652, 2019.

[24] J. T. Lordan, R. Heywood, S. Shirol, and D. P. Edwards, “Following anterior resection for rectal cancer, defunctioning ileostomy closure may be significantly delayed by adjuvant chemotherapy: a retrospective study,” *Colorectal Disease*, vol. 9, no. 5, pp. 420–422, 2007.

[25] C. P. Gustafsson, U. Gunnarsson, U. Dahlstrand, and U. Lindford, “Loop–ileostomy reversal-patient-related characteristics influencing time to closure,” *International Journal of Colorectal Disease*, vol. 33, no. 5, pp. 593–600, 2018.

[26] P. Waterland, K. Goonetilleke, D. N. Naumann, M. Sutcliffe, and F. Soliman, “Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies,” *Journal of Clinical Medicine Research*, vol. 7, pp. 685–689, 2015.

[27] J. Camilleri-Brennan and R. J. Steele, “Prospective analysis of quality of life after reversal of a defunctioning loop ileostomy,” *Colorectal Disease*, vol. 4, no. 3, pp. 167–171, 2002.

[28] M. F. Martens and T. Hendriks, “Postoperative changes in collagen synthesis in intestinal anastomoses of the rat: differences between small and large bowel,” *Gut*, vol. 32, no. 12, pp. 1482–1487, 1991.

[29] J. M. Straub, J. New, C. D. Hamilton, C. Lominska, Y. Shnayder, and S. M. Thomas, “Radiation-induced fibrosis: mechanisms and implications for therapy,” *Journal of Cancer Research and Clinical Oncology*, vol. 141, no. 11, pp. 1985–1994, 2015.

[30] N. Pokharel, G. Katwal, and S. K. Adhikari, “Comparison of preoperative nutritional risk index and body mass index for predicting immediate postoperative outcomes following major gastrointestinal surgery: cohort-study,” *Annals of Medicine and Surgery*, vol. 48, pp. 53–58, 2019.

[31] T. Hensler, H. Hecker, K. Heeg et al., “Distinct mechanisms of immunosuppression as a consequence of major surgery,” *Infection and Immunity*, vol. 65, no. 6, pp. 2283–2291, 1997.
surrounding reversal of defunctioning ileostomies: a systematic review of 48 studies including 6,107 cases,” *International Journal of Colorectal Disease*, vol. 24, no. 6, pp. 711–723, 2009.

[33] S. B. Lim, C. S. Yu, C. W. Kim, Y. S. Yoon, I. J. Park, and J. C. Kim, "Late anastomotic leakage after low anterior resection in rectal cancer patients: clinical characteristics and predisposing factors," *Colorectal Disease*, vol. 18, no. 4, pp. O135–O140, 2016.

[34] C. Keane, N. S. Fearnhead, L. G. Bordeianou et al., "International consensus definition of low anterior resection syndrome," *Diseases of the Colon and Rectum*, vol. 63, no. 3, pp. 274–284, 2020.

[35] A. M. Roe, B. F. Warren, A. J. Brodribb, and C. Brown, "Diversion colitis and involution of the defunctioned anorectum,” *Gut*, vol. 34, no. 3, pp. 382–385, 1993.

[36] S. J. Baek, S. H. Kim, C. K. Lee et al., "Relationship between the severity of diversion colitis and the composition of colonic bacteria: a prospective study,” *Gut Liver*, vol. 8, no. 2, pp. 170–176, 2014.

[37] N. J. Battersby, G. Bouliotis, K. J. Emmertsen et al., "Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score," *Gut*, vol. 67, p. gutjnl-2016-312695, 2018.

[38] L. M. Jimenez-Gomez, E. Espin-Basany, L. Trenti et al., "Factors associated with low anterior resection syndrome after surgical treatment of rectal cancer," *Colorectal Disease*, vol. 20, no. 3, pp. 195–200, 2017.

[39] F. Herrle, F. Sandra-Petrescu, C. Weiss, S. Post, N. Runkel, and P. Kienle, "Quality of life and timing of stoma closure in patients with rectal cancer undergoing low anterior resection with diverting stomas: a multicenter longitudinal observational study,” *Diseases of the Colon and Rectum*, vol. 59, no. 4, pp. 281–290, 2016.

[40] O. Hallböök and R. Sjödahl, "Surgical approaches to obtaining optimal bowel function,” *Seminars in Surgical Oncology*, vol. 18, no. 3, pp. 249–258, 2000.

[41] R. Lindgren, O. Hallböök, J. Rutegård, R. Sjödahl, and P. Matthiessen, "Does a defunctioning stoma affect anorectal function after low rectal resection? Results of a randomized multicenter trial,” *Diseases of the Colon and Rectum*, vol. 54, no. 6, pp. 747–752, 2011.